Last reviewed · How we verify
Placebo-matching Rapastinel
Rapastinel is an NMDA receptor modulator that enhances glutamatergic neurotransmission by potentiating NMDA receptor function to improve cognitive and psychiatric symptoms.
Rapastinel is an NMDA receptor modulator that enhances glutamatergic neurotransmission by potentiating NMDA receptor function to improve cognitive and psychiatric symptoms. Used for Major depressive disorder (as adjunctive treatment), Cognitive impairment associated with schizophrenia.
At a glance
| Generic name | Placebo-matching Rapastinel |
|---|---|
| Sponsor | Naurex, Inc, an affiliate of Allergan plc |
| Drug class | NMDA receptor modulator |
| Target | NMDA receptor (N-methyl-D-aspartate receptor) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | Phase 3 |
Mechanism of action
Rapastinel acts as an allosteric modulator of the NMDA receptor, a key ionotropic glutamate receptor involved in synaptic plasticity and learning. By enhancing NMDA receptor-mediated neurotransmission, it is designed to improve cognitive deficits and potentially treat psychiatric disorders. The drug targets the glycine-binding site on the NMDA receptor to potentiate its activity.
Approved indications
- Major depressive disorder (as adjunctive treatment)
- Cognitive impairment associated with schizophrenia
Common side effects
- Dizziness
- Headache
- Nausea
- Somnolence
Key clinical trials
- A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder (PHASE2)
- A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder (PHASE3)
- A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02) (PHASE3)
- A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03) (PHASE3)
- A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01) (PHASE3)
- Assessment of Effect of Rapastinel on Driving Performance (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo-matching Rapastinel CI brief — competitive landscape report
- Placebo-matching Rapastinel updates RSS · CI watch RSS
- Naurex, Inc, an affiliate of Allergan plc portfolio CI